Document is current
Any future updates will be listed below
-
Authors
Fendler, Annika https://orcid.org/0000-0002-7267-0981
de Vries, Elisabeth G. E. https://orcid.org/0000-0002-8949-7425
GeurtsvanKessel, Corine H.
Haanen, John B. https://orcid.org/0000-0001-5884-7704
Wörmann, Bernhard
Turajlic, Samra https://orcid.org/0000-0001-8846-136X
von Lilienfeld-Toal, Marie https://orcid.org/0000-0002-9756-3541
- License Information
-
More Information
Article History
Accepted: 15 February 2022
First Online: 11 March 2022
Competing interests
: E.G.E. de V has acted as an advisor and/or consultant to Crescendo Biologics, Daiichi Sankyo and NSABP, declares financial support for clinical trials and/or contract research from Amgen, Bayer, Crescendo Biologics, G1 Therapeutics, Genentech, Regeneron, Roche, Servier and Synthon, and declares unpaid roles as a co-chair of the RECIST committee, as a chair of the ESMO Cancer Medicines Committee, as a member of the ESMO-MCBS working party, as a member of the expert panel for the selection of Essential Medicines List WHO, as a member of the Royal Netherlands Academy of Arts & Sciences and as a member of the supervisory board of the Netherlands Comprehensive Cancer Organization, and is a Project leader of the ZOnMw-funded Vaccination against cOvid In CancEr (VOICE) study. J.B.H. has acted as an advisor to Achilles Therapeutics, AstraZeneca, Bristol Myers Squibb, BioNTech, Immunocore, Ipsen, Instil Bio, Iovance Bio, MSD, Merck Serono, Molecular Partners, Novartis, Neogene Therapeutics, Pfizer, Roche/Genentech, Sanofi and T-Knife, has received research funding from Asher Bio, Amgen, Bristol Myers Squibb, MSD, BioNTech, Neogene Therapeutics and Novartis, has stock options in Neogene therapeutics, and is the current Editor-in-Chief of ESMO Immuno-Oncology and Technology. S.T. has received speaker’s fees from AstraZeneca, Ipsen, Novartis and Roche, and is listed on the following patents: Indel mutations as a therapeutic target and predictive biomarker (PCTGB2018/051892 and PCTGB2018/051893, as inventor) and Clear Cell Renal Cell Carcinoma Biomarkers (P113326GB, as co-inventor). M.v.L.T. has received speaker’s fees from Abbvie, Amgen, AstraZeneca, BMS, CDDF, Celgene, Chugai, GSK, Gilead, Janssen, Medac, Merck, Novartis, Oncopeptides, Pfizer, Shionogi, Takeda and Thermofisher, and research funding from BMBF, Celgene, Deutsche Jose Carreras Leukämie-Stiftung, Deutsche Krebshilfe, DFG, Gilead, IZKF Jena, Novartis and Oncopeptides. A.F., C.H.G., and B.W. declare no competing interests.
Free to read: This content has been made available to all.
